Compare WHWK & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHWK | ABOS |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.8M | 165.6M |
| IPO Year | 2017 | 2021 |
| Metric | WHWK | ABOS |
|---|---|---|
| Price | $3.01 | $0.20 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 6 |
| Target Price | ★ $7.71 | $1.00 |
| AVG Volume (30 Days) | 366.3K | ★ 5.5M |
| Earning Date | 11-09-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.02 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,145,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.97 | $0.19 |
| 52 Week High | $5.50 | $3.60 |
| Indicator | WHWK | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 20.91 |
| Support Level | $2.88 | $0.19 |
| Resistance Level | $3.88 | $2.84 |
| Average True Range (ATR) | 0.21 | 0.06 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 12.50 | 0.39 |
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.